Loading stock data…
$14.37-0.55 (-3.69%)
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States.
Cullinan Therapeutics, Inc. in the Healthcare sector is trading at $14.37 with a market capitalization of $1.3B. Wall Street consensus targets $34.50 (10 analysts), implying a +140.1% move over the next 12 months. The stock is currently 38% below its 52-week high of $23.19, remaining 8.5% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$57.25M↓ | -$53.70M↑ | -$55.26M↑ | -$55.59M↑ | -$75.80M |
| Net Income | -$53.70M↓ | -$49.66M↑ | -$50.71M↓ | -$50.61M↑ | -$70.06M |
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune disease...